A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

Key Inclusion Criteria: Recent-onset stage 3 T1D diagnosed by standard ADA criteria, with the ability to be randomized within 6 months from the date of T1D diagnosis and within 37 days of Screening Visit. * At least one positive T1D auto-antibody. * If clearly positive (≥20% above local lab's ULN) at screening, repeat antibody testing for central lab is not required. * Insulin auto-antibodies are only considered if exogenous insulin use is \<10 days when blood is drawn. * Must have stimulated C-peptide levels ≥0.2 pmol/mL measured during MMTT conducted prior to randomization. * Age 9 to \<21 years at the time of randomization. * Body weight \>30kg. * BMI \<95th percentile for age and gender. * Willing to comply with intensive diabetes management. * Female participants with childbearing potential are not currently pregnant, are willing to avoid pregnancy and breastfeeding, and to undergo pregnancy testing prior to MMTTs for the duration of the study. * Women of childbearing potential (WOCBP) must use an acceptable form of birth control. Acceptable forms include oral/injection contraceptives, transdermal contraceptives, diaphragm, intrauterine devices, condoms with spermicide, documented surgical sterilization of either the participant or their partner or abstinence. * Male participants with potential to father children must be willing to use abstinence or adequate contraceptive methods for the duration of the study. * Males must agree to be sexually abstinent or use a condom…